biostudies-literatureUnknown10(9)Martelli V<h4>Background</h4>Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular response is an unmet clinical need. Liquid biopsy-RECIST (LB-RECIST), based on aggregate variant allele frequency (aggVAF; sum of all detected variant allele frequencies in a sample) variations, has been proposed to stratify molecular response. Metastatic colorectal cancer (mCRC) may be an attractive clinical scenario for LB-RECIST clinical implementation; however, specific data on clinical validity is still lacking.<h4>Patients and methods</h4>The prospective PLATFORM-B study enrolled 130 mCRC patients who received standard frontline treatment and underwent serial ctESMO open105760https://www.ebi.ac.uk/biostudies/studies/S-EPMC12446507biostudies-literatureClinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.PMC12446507Elez EFerreiro RManzano JLAlonso VMartelli VPineda EBellosillo BMontagut CGibert JGomez-Espana MAToledo RSalazar RLosa FAranda EPaez DGuix MCano MTGarcia-Alfonso PSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Tabernero JSibilio ALinares JFernandez-Rodriguez MCSantos CRivera FVidal JDuran GGarcia-Carbonero RSastre JfalseClinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.<h4>Background</h4>Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular response is an unmet clinical need. Liquid biopsy-RECIST (LB-RECIST), based on aggregate variant allele frequency (aggVAF; sum of all detected variant allele frequencies in a sample) variations, has been proposed to stratify molecular response. Metastatic colorectal cancer (mCRC) may be an attractive clinical scenario for LB-RECIST clinical implementation; however, specific data on clinical validity is still lacking.<h4>Patients and methods</h4>The prospective PLATFORM-B study enrolled 130 mCRC patients who received standard frontline treatment and underwent serial ct2025-01-01T00:00:00Z2025 Sep2026-06-03T14:29:06.795Z2026-04-28T03:11:41.127ZS-EPMC124465074090720710.1016/j.esmoop.2025.105760